EA024563B1 - Применение с-мет-модуляторов в комбинированной терапии рака - Google Patents

Применение с-мет-модуляторов в комбинированной терапии рака Download PDF

Info

Publication number
EA024563B1
EA024563B1 EA201270247A EA201270247A EA024563B1 EA 024563 B1 EA024563 B1 EA 024563B1 EA 201270247 A EA201270247 A EA 201270247A EA 201270247 A EA201270247 A EA 201270247A EA 024563 B1 EA024563 B1 EA 024563B1
Authority
EA
Eurasian Patent Office
Prior art keywords
administered
fluorophenyl
phenyl
quinolin
oxy
Prior art date
Application number
EA201270247A
Other languages
English (en)
Russian (ru)
Other versions
EA201270247A1 (ru
Inventor
Дана Т. Афтаб
Томас Мюллер
Аарон Вейцман
Джеймс Холланд
Original Assignee
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экселиксис, Инк. filed Critical Экселиксис, Инк.
Publication of EA201270247A1 publication Critical patent/EA201270247A1/ru
Publication of EA024563B1 publication Critical patent/EA024563B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201270247A 2009-08-07 2010-08-06 Применение с-мет-модуляторов в комбинированной терапии рака EA024563B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23238209P 2009-08-07 2009-08-07
PCT/US2010/044749 WO2011017639A1 (en) 2009-08-07 2010-08-06 Methods of using c-met modulators

Publications (2)

Publication Number Publication Date
EA201270247A1 EA201270247A1 (ru) 2012-11-30
EA024563B1 true EA024563B1 (ru) 2016-09-30

Family

ID=42668075

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201270247A EA024563B1 (ru) 2009-08-07 2010-08-06 Применение с-мет-модуляторов в комбинированной терапии рака
EA201500300A EA029585B1 (ru) 2009-08-07 2010-08-06 СПОСОБ ПОЛУЧЕНИЯ c-Met-МОДУЛЯТОРОВ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201500300A EA029585B1 (ru) 2009-08-07 2010-08-06 СПОСОБ ПОЛУЧЕНИЯ c-Met-МОДУЛЯТОРОВ

Country Status (17)

Country Link
US (5) US20120282179A1 (enExample)
EP (1) EP2461810A1 (enExample)
JP (3) JP5933435B2 (enExample)
KR (2) KR101954322B1 (enExample)
CN (2) CN102647985A (enExample)
AU (2) AU2010279234B2 (enExample)
BR (1) BR112012002759A2 (enExample)
CA (2) CA2770100C (enExample)
EA (2) EA024563B1 (enExample)
GE (2) GEP201606521B (enExample)
HK (1) HK1246291A1 (enExample)
IL (2) IL217889A (enExample)
MX (2) MX356176B (enExample)
NZ (2) NZ598055A (enExample)
UA (2) UA108618C2 (enExample)
WO (1) WO2011017639A1 (enExample)
ZA (1) ZA201200842B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436888T3 (es) 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
CA2752421C (en) 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
IL224189A (en) 2010-07-16 2017-07-31 Exelixis Inc C-met modulator pharmaceutical compositions
JP6158705B2 (ja) 2010-09-27 2017-07-05 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
KR20210147117A (ko) 2011-02-10 2021-12-06 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CA2848512A1 (en) 2011-09-22 2013-03-28 Exelixis, Inc. Method for treating osteoporosis
MX343288B (es) 2011-10-20 2016-11-01 Exelixis Inc Proceso para la preparación de derivados de quinolina.
US20140323522A1 (en) * 2011-11-08 2014-10-30 Exelixis, Inc. Method of Treating Cancer
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
US20150203453A1 (en) 2012-10-02 2015-07-23 Epitherapeutics Aps Inhibitors of histone demethylases
JP6514117B2 (ja) 2013-02-27 2019-05-15 エピセラピューティクス アーペーエス ヒストン脱メチル化酵素の阻害剤
BR112015023109A2 (pt) 2013-03-15 2018-05-15 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida
CN108472242A (zh) * 2013-04-04 2018-08-31 埃克塞里艾克西斯公司 治疗癌症的药物组合
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
CN103664778B (zh) * 2013-11-27 2017-04-05 苏州摩尔医药有限公司 一种抗肿瘤治疗药物卡博替尼的合成方法
UA123534C2 (uk) 2014-02-14 2021-04-21 Екселіксис, Інк. Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування
JP6666849B2 (ja) * 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
AR099890A1 (es) 2014-03-31 2016-08-24 Epitherapeutics Aps Inhibidores de histona demetilasas
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma
CA2957947A1 (en) 2014-08-27 2016-03-03 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases
CN105747477B (zh) * 2016-02-25 2017-10-24 吴栢涛 一种反重力双肩背包
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
CN106831707B (zh) * 2016-12-28 2019-09-20 杭州市西溪医院 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途
CN110621662B (zh) 2017-05-26 2023-06-23 埃克塞里艾克西斯公司 一种盐的结晶性固体形式、制备工艺和使用方法
BR112020015199A2 (pt) 2018-01-26 2021-05-04 Exelixis, Inc. compostos para o tratamento de distúrbios dependentes de quinase
CA3088198A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
US11542259B2 (en) 2018-01-26 2023-01-03 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN109988110B (zh) * 2019-01-22 2022-07-01 威海海洋生物医药产业技术研究院有限公司 4-苯氧基喹啉并磺酰脲类化合物、合成该化合物的中间体及其制备方法和用途
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
CN120239695A (zh) * 2022-12-01 2025-07-01 江苏奥赛康药业有限公司 一种制备卡博替尼及其中间体的方法
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2006014420A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
US20060199843A1 (en) * 2002-05-17 2006-09-07 Zeldis Jerome B Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2008076415A1 (en) * 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
JPS646261A (en) 1987-03-31 1989-01-10 Nisshin Flour Milling Co 4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5034393A (en) 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5238951A (en) 1991-02-01 1993-08-24 E. R. Squibb & Sons, Inc. Heterocyclic amido prostaglandin analogs
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
SK72996A3 (en) 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
JPH11507052A (ja) 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9526546D0 (en) 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP2001500890A (ja) 1996-09-25 2001-01-23 ゼネカ リミテッド Ｖｅｇｆのような成長因子の作用を阻害するキノリン誘導体
JP4073961B2 (ja) 1996-10-01 2008-04-09 協和醗酵工業株式会社 含窒素複素環化合物
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
JP4303792B2 (ja) 1997-04-18 2009-07-29 協和発酵キリン株式会社 キノロン誘導体の製造方法
DE69818248T2 (de) 1997-04-22 2004-06-17 Janssen Pharmaceutica N.V. Chinolin- und chinazolin-derivate als crf antagonisten
GB9708917D0 (en) 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
IL141434A0 (en) 1998-08-21 2002-03-10 Parker Hughes Inst Quinazoline derivatives
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1143950B1 (de) 1998-09-10 2005-03-09 BioEqual AG Topisch anwendbare mittel gegen nagelpilzerkrankungen
EA004436B1 (ru) 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
ES2191462T3 (es) 1998-10-01 2003-09-01 Astrazeneca Ab Derivados de quinolina y quinazolina y su uso como inhibidores de enfermedades mediadas por citoquinas.
ATE294796T1 (de) 1998-10-08 2005-05-15 Astrazeneca Ab Chinazolin derivate
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
AU771504B2 (en) 1999-01-22 2004-03-25 Kyowa Hakko Kirin Co., Ltd. Quinoline derivatives and quinazoline derivatives
PL199802B1 (pl) 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU3630100A (en) 1999-03-19 2000-10-09 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6126917A (en) 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
EP1194418A1 (de) 1999-06-21 2002-04-10 Boehringer Ingelheim Pharma KG Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CZ20021009A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003518023A (ja) 1999-11-30 2003-06-03 パーカー ヒューズ インスティテュート トロンビン誘導血小板凝集の阻害剤
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
WO2001047890A1 (en) 1999-12-24 2001-07-05 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
JP2003520855A (ja) 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
US6664390B2 (en) 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
US7091227B2 (en) 2000-02-07 2006-08-15 Abbott Gmbh & Co. Kg Benzothiazole derivatives
KR20080009294A (ko) 2000-03-13 2008-01-28 와이어쓰 홀딩스 코포레이션 시아노퀴놀린을 포함하는 결장 폴립의 치료 또는 억제를위한 약제학적 조성물
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
HUP0301120A2 (hu) 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
EP1174118A1 (de) 2000-06-28 2002-01-23 Cognis France S.A. Verwendung von Inulinen und Inulinderivaten
MXPA02011974A (es) 2000-06-28 2004-09-06 Astrazeneca Ab Derivados de quinazolina sustituidos y su uso como inhibidores.
FR2811658B1 (fr) 2000-07-17 2004-07-02 Cfpi Nufarm Reacteur biologique a lit fixe immerge et procede de traitement d'effluents liquides
US7427689B2 (en) 2000-07-28 2008-09-23 Georgetown University ErbB-2 selective small molecule kinase inhibitors
CZ2003486A3 (cs) 2000-08-21 2003-05-14 Astrazeneca Ab Chinazolinové deriváty, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
AU2001292137A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
JP2004511479A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
WO2002034744A1 (en) 2000-10-25 2002-05-02 Astrazeneca Ab Quinazoline derivatives
WO2002044166A1 (en) 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents
EP1340748B1 (en) 2000-11-02 2008-01-16 Nippon Shinyaku Co., Ltd. Quinazoline derivatives and drugs
AU2001295791A1 (en) 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US7141577B2 (en) 2001-04-19 2006-11-28 Astrazeneca Ab Quinazoline derivatives
BRPI0209216B8 (pt) 2001-04-27 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
DE10125432A1 (de) 2001-05-25 2002-11-28 Bayer Ag Substituierte Benzoylketone
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
KR100397792B1 (ko) 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
GB0118752D0 (en) 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030066060A1 (en) 2001-09-28 2003-04-03 Ford Richard L. Cross profile guided optimization of program execution
WO2003033472A1 (en) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
US6821988B2 (en) 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
AU2002347336A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
WO2003047584A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
JP4202926B2 (ja) 2001-12-12 2008-12-24 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−（４−（３−メチル−ピリジン−３−イロキシ）−フェニルアミノ）−キナゾリン−６−イル）−アリル）−アセトアミドの塩形態、その製造および癌に対するその使用
EP1465632A1 (en) 2001-12-12 2004-10-13 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
AU2002361846A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
JP4498741B2 (ja) 2001-12-24 2010-07-07 アストラゼネカ アクチボラグ オーロラキナーゼ阻害剤としての置換キナゾリン誘導体
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
WO2003064421A1 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine derivatives
NZ534171A (en) 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
DE10217689A1 (de) 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
WO2003093238A1 (en) 2002-05-01 2003-11-13 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
EP1548008A4 (en) 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
US7419984B2 (en) 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
JP3763414B2 (ja) 2002-10-21 2006-04-05 麒麟麦酒株式会社 Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
US20080207617A1 (en) 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
CA2509239A1 (en) 2002-12-13 2004-07-01 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
CA2510323A1 (en) 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
US7238679B2 (en) 2002-12-23 2007-07-03 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
AU2003292838A1 (en) 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
US7662783B2 (en) * 2003-02-20 2010-02-16 New York University CLK-peptide and SLK-peptide
US8176532B1 (en) 2003-03-17 2012-05-08 Sprint Communications Company L.P. Secure access point for scada devices
KR100559180B1 (ko) 2003-05-20 2006-03-14 김민서 조건부 거래에 따른 전자결제 방법 및 전자결제 서버
WO2005003140A1 (en) 2003-07-02 2005-01-13 Pharmacia & Upjohn Company Llc 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
WO2005005389A2 (en) 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
KR101224410B1 (ko) 2003-11-07 2013-01-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 퀴놀리논 화합물을 합성하는 방법
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
CA2603748A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
WO2007062135A2 (en) 2005-11-23 2007-05-31 Junji Shiraishi Computer-aided method for detection of interval changes in successive whole-body bone scans and related computer program product and system
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
MX2008012485A (es) * 2006-03-30 2008-10-10 Novartis Ag Composiciones y metodos de uso para anticuerpos de c-met.
US20080004273A1 (en) 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR101380444B1 (ko) 2006-08-23 2014-04-01 에자이 알앤드디 매니지먼트 가부시키가이샤 페녹시피리딘 유도체의 염 또는 그 결정 및 이들의 제조 방법
JPWO2009096435A1 (ja) * 2008-01-29 2011-05-26 武田薬品工業株式会社 縮合複素環誘導体およびその用途
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
US8445509B2 (en) * 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
JP2012504606A (ja) 2008-10-01 2012-02-23 ラディック インスティテュート フォー キャンサー リサーチ 癌の治療方法
MX2011005038A (es) 2008-11-13 2011-06-16 Exelisis Inc Metodo de preparacion de derivados de quinolina.
EP2367795A1 (en) 2008-12-04 2011-09-28 Exelixis, Inc. Methods of preparing quinoline derivatives
CA2995880C (en) * 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
TW201118072A (en) 2009-07-17 2011-06-01 Exelixis Inc Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20110059081A1 (en) 2009-09-09 2011-03-10 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
JP2013522232A (ja) 2010-03-12 2013-06-13 エグゼリクシス， インコーポレイテッド Ｎ−［３−フルオロ−４−（｛６−（メチロキシ）−７−［（３−モルホリン−４−イルプロピル）オキシ］−キノリン−４−イル｝オキシ）フェニル］−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボサミドの水和結晶性形状
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
IL224189A (en) 2010-07-16 2017-07-31 Exelixis Inc C-met modulator pharmaceutical compositions
US20140186407A9 (en) 2010-07-16 2014-07-03 Exelixis Inc. C-Met Modulator Pharmaceutical Compositions
EP2643001A4 (en) 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
US20140323522A1 (en) 2011-11-08 2014-10-30 Exelixis, Inc. Method of Treating Cancer
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
ES2726605T3 (es) 2012-09-07 2019-10-08 Exelixis Inc Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón
CN108472242A (zh) 2013-04-04 2018-08-31 埃克塞里艾克西斯公司 治疗癌症的药物组合
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060199843A1 (en) * 2002-05-17 2006-09-07 Zeldis Jerome B Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2006014420A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
WO2008076415A1 (en) * 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors

Also Published As

Publication number Publication date
JP2017082007A (ja) 2017-05-18
WO2011017639A1 (en) 2011-02-10
IL217889A0 (en) 2012-03-29
EA201500300A1 (ru) 2015-10-30
KR20120059540A (ko) 2012-06-08
MX356176B (es) 2018-05-17
CN107325048A (zh) 2017-11-07
EA029585B1 (ru) 2018-04-30
GEP201606521B (en) 2016-08-10
JP5933435B2 (ja) 2016-06-08
US20230181559A1 (en) 2023-06-15
AU2017200269A1 (en) 2017-02-02
AU2017200269B2 (en) 2019-02-07
AU2010279234B2 (en) 2016-10-20
GEP20156310B (en) 2015-07-10
AU2010279234A1 (en) 2012-03-01
IL238849A (en) 2017-11-30
EA201270247A1 (ru) 2012-11-30
KR101954322B1 (ko) 2019-03-05
US20200330451A1 (en) 2020-10-22
US10736886B2 (en) 2020-08-11
IL217889A (en) 2015-06-30
US20120282179A1 (en) 2012-11-08
KR20170087966A (ko) 2017-07-31
US20160000772A1 (en) 2016-01-07
CA3002945A1 (en) 2011-02-10
ZA201200842B (en) 2012-11-28
NZ624643A (en) 2015-11-27
CA2770100A1 (en) 2011-02-10
US20190151302A1 (en) 2019-05-23
MX2012001654A (es) 2012-03-14
JP2013501731A (ja) 2013-01-17
CA3002945C (en) 2021-10-19
CN102647985A (zh) 2012-08-22
HK1246291A1 (zh) 2018-09-07
JP6317775B2 (ja) 2018-04-25
KR101761380B1 (ko) 2017-07-25
NZ598055A (en) 2014-05-30
US11433064B2 (en) 2022-09-06
UA119316C2 (uk) 2019-06-10
JP2016106141A (ja) 2016-06-16
CA2770100C (en) 2021-04-20
UA108618C2 (uk) 2015-05-25
BR112012002759A2 (pt) 2019-09-24
EP2461810A1 (en) 2012-06-13
IL238849A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
EA024563B1 (ru) Применение с-мет-модуляторов в комбинированной терапии рака
US11969419B2 (en) Method of treating cancer
US20240316030A1 (en) Method of treating cancer and bone cancer pain
US9861624B2 (en) Method of treating cancer
CN110305123B (zh) 一种含有金刚烷的化合物及其在治疗癌症中的用途
CN111166744B (zh) 4-(苯并噻唑-2-基)芳胺类化合物治疗胃癌的用途
KR20220104734A (ko) 올레아난 신남아미드 유도체 및 이의 제조 방법과 용도

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM